Screener
Harrow HROW VEVYE — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Harrow’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-022254
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| IHEEZO | $1,851,000 | $5,222,000 |
| VEVYE | 20,947,000 | 21,516,000 |
| Other branded products | 7,833,000 | 956,000 |
| Other revenues | 73,000 | 86,000 |
| Branded revenue, net | 30,704,000 | 27,780,000 |
| Compounding revenue, net | 13,499,000 | 20,051,000 |
| Total revenues, net | $44,203,000 | $47,831,000 |
Item 1. Financial Statements (unaudited) Item
FAQ
- What is Harrow's VEVYE — revenue?
- Harrow (HROW) reported VEVYE — revenue of $20.95M in Q1 2026.
- How has Harrow's VEVYE — revenue changed year-over-year?
- Harrow's VEVYE — revenue decreased by 2.6% year-over-year, from $21.52M to $20.95M.
- What is the long-term trend for Harrow's VEVYE — revenue?
- Over 2 years (2023 to 2025), Harrow's VEVYE — revenue has grown at a 608.7% compound annual growth rate (CAGR), from $1.77M to $88.69M.
- What does VEVYE — revenue mean?
- This metric represents the total net revenue generated from the sale of a specific pharmaceutical product or service line after adjusting for taxes collected from customers. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line growth. Tracking this figure allows investors to evaluate the scaling trajectory and demand for the specific asset within the company's portfolio.
Ask your AI about Harrow's vevye — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude